Altimmune Presents New Data on Pemvidutide’s Benefits for Liver Disease and Obesity at EASL Congress
Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflammatory and anti-fibrotic properties of pemvidutide in Metabolic Dysfunction-Associated